Fate Therapeutics Inc
NASDAQ:FATE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Epwin Group PLC
LSE:EPWN
|
UK |
|
Husqvarna AB
STO:HUSQ B
|
SE |
|
N
|
Nexus Minerals Ltd
ASX:NXM
|
AU |
|
Ayala Land Inc
OTC:AYAAF
|
PH |
|
Boyaa Interactive International Ltd
HKEX:434
|
CN |
Fate Therapeutics Inc
Non-Reccuring Items
Fate Therapeutics Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fate Therapeutics Inc
NASDAQ:FATE
|
Non-Reccuring Items
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
Fate Therapeutics Inc
Glance View
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 449 full-time employees. The company went IPO on 2013-10-01. The firm is focused on the development of programmed cellular immunotherapies for patients with cancer. The company uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The firm is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The firm's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
See Also
What is Fate Therapeutics Inc's Non-Reccuring Items?
Non-Reccuring Items
0
USD
Based on the financial report for Dec 31, 2025, Fate Therapeutics Inc's Non-Reccuring Items amounts to 0 USD.
